IL6 and diabetic kidney disease: Moreover, SGLT2i have been shown to decrease the circulating levels of IL-6, tumor necrosis factor receptor-1 (TNF receptor-1), matrix metalloproteinase-7, and fibronectin-1, all acting on essential key points in diabetic kidney disease.